---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-033215"
form_type: "8-K"
ticker: "CLDI"
cik: "0001855485"
company_name: "Calidi Biotherapeutics, Inc."
filed_at: "2024-08-20T23:59:59+00:00"
generated_at: "2026-05-31T08:31:25.960941+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Director George Ng to step down at 2024 annual meeting; Board reduced to 5

## Summary
- George Ng will allow his director term to expire at the Company's 2024 annual shareholder meeting.
- Board size reduced from six to five directors effective the date of the 2024 annual meeting.
- Mr. Ng will continue as a strategic advisor and consultant to the Company.
- Departure not due to any disagreement with Company operations, policies, or practices.

## SEC filing metadata
- accession: 0001493152-24-033215
- form_type: 8-K
- ticker: CLDI
- cik: 0001855485
- company_name: Calidi Biotherapeutics, Inc.
- filed_at: 2024-08-20T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855485/000149315224033215/0001493152-24-033215-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855485/000149315224033215/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-033215
- JSON: https://secwatch.observer/filing/0001493152-24-033215.json
- Plain text: https://secwatch.observer/filing/0001493152-24-033215.txt

## Key facts
- Executive change
  George Ng departed as Director at Calidi Biotherapeutics, Inc..
  - Action: allowed term to expire
  - Role: Director
  source text: On August 16, 2024, Mr. George Ng, a member of the Board of Directors (the “Board”) of Calidi Biotherapeutics, Inc. (the “Company”), informed the Board that, in order to focus on increasing professional commitments outside of the Company, he intends to allow the term of his Director position on the Board to expire, which expiration date is scheduled to be the date of the Company’s 2024 annual shareholder meeting.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1855485/000149315224033215/0001493152-24-033215-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.